This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahamed, J.
Right arrow Articles by Kundu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahamed, J.
Right arrow Articles by Kundu, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1999, p. 2081-2083, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Molecular Characterization of the SHV-11 beta -Lactamase of Shigella dysenteriae

Jasimuddin Ahamed and Manikuntala Kundu*

Department of Chemistry, Bose Institute, Calcutta 700 009, India

Received 16 November 1998/Returned for modification 3 March 1999/Accepted 6 June 1999


    ABSTRACT
Top
Abstract
Text
References

A beta -lactamase with an Mr of 29,000 and a pI of 7.6 was partially purified from a clinical isolate of Shigella dysenteriae. The bla gene encoded the SHV-11 enzyme carrying the substitution Leuright-arrowGln at position 35 and was linked to a strong promoter. This variant, unlike the prototype SHV-1 enzyme, hydrolyzed oxacillin, cloxacillin, and oxyiminocephalosporins such as cefotaxime.


    TEXT
Top
Abstract
Text
References

Shigella species are a major cause of diarrheal diseases and mortality in developing countries (4), and the frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and streptomycin is causing growing concern. beta -Lactamases are primarily responsible for beta -lactam resistance in gram-negative bacteria. The presence of TEM-, OXA-1, and OXA-3 beta -lactamases in S. flexneri and S. sonnei has been previously reported (21). However, detailed characterization of these enzymes in S. dysenteriae is lacking. We report a clinical strain of S. dysenteriae PB-10 (obtained from the National Institute of Cholera and Enteric Diseases [NICED], Calcutta, India) harboring the SHV-11 beta -lactamase capable of hydrolyzing oxacillin, cloxcillin, and oxyimnocephalosporins.

Bacteria were routinely grown in tryptic soy broth on a rotary shaker at 37°C. The beta -lactamase was partially purified from sonic extracts of cells by size-exclusion chromatography on Sephadex G-75, followed by successive chromatography on a Q-Sepharose anion exchanger at pH 7 (at which time beta -lactamase activity remained in the flowthrough) and then at pH 10 (where beta -lactamase activity eluted at a salt concentration of 0.1 M NaCl in 20 mM ethanolamine containing 5% glycerol and 5% ethylene glycol). During purification of the enzyme, beta -lactamase activity was routinely determined at 30°C by monitoring the hydrolysis of nitrocefin spectrophotometrically at 482 nm (17). One unit of beta -lactamase activity is the amount of enzyme hydrolyzing 1 µmol of nitrocefin per min.

Hydrolysis of beta -lactams was monitored at 30°C in 100 mM sodium phosphate buffer, pH 7.2, at wavelengths that gave a maximum in the difference spectrum of the hydrolyzed antibiotic against the unhydrolyzed antibiotic. The relative Vmax values of the substrates were obtained after absorbance data were fit to the integrated Michaelis-Menten equation (7). The rate of hydrolysis of benzylpenicillin was set at 100.

Conjugative transfer of S. dysenteriae PB-10 antibiotic resistance plasmid into Escherichia coli HB-101 was performed as described previously by Philippon et al. (18). Transconjugants were selected by plating on medium containing 25 µg of ampicillin/ml and 10 µg of rifampin/ml.

For cloning of the beta -lactamase gene, plasmid DNA from the transconjugant was partially digested with BamHI and ligated to the BamHI-digested vector pK19 (20). Transformants were selected on Luria-Bertani agar supplemented with 1 mM isopropyl-beta -D-thiogalactopyranoside (IPTG), 50 µg of ampicillin, and 50 µg of kanamycin per ml. Plasmid DNA containing an approx 9-kb insert was subsequently subcloned in several steps by using successively the enzymes SstI, SaII, and AvaI and selecting each time for Amp Kanr recombinants. The plasmid obtained in the final step, pMK105, contained a 1.8-kb insert. A library of nested deletions of the clone pMK105 was finally generated in the vector pK19 to sequence the entire cloned DNA, by using the double-stranded nested deletion kit from Amersham Pharmacia Biotech. DNA sequencing was done by using the Thermosequenase cycle sequencing kit (Amersham Pharmacia Biotech). Both strands of DNA were sequenced from two clones. The nucleotide sequence and the deduced protein sequence were analyzed by using the Genetics Computer Group software package. Similarity searches were performed by using the Gap BLAST algorithm (1).

The beta -lactam resistance of strain PB10 could be transferred to a rifampin-resistant strain of E. coli, HB101, by transconjugation. MICs were determined on Mueller-Hinton agar plates containing serial dilutions of antibiotics by inoculating with 104 CFU per spot and reading after 18 h of growth at 37°C. The clinical isolate PB-10 was resistant toward all the penicillins and some of the cephalosporins tested (Table 1). Cefoxitin and imipenem appeared to be the most effective antibiotics. The MICs of selected antibiotics were determined in combination with that of clavulanic acid (MIC, 32 µg/ml) at a concentration of 4 µg/ml. The decreased MICs indicated the involvement of a transferable beta -lactamase resistant to strain PB-10. The cefotaxime and ceftazidime MICs are high compared to data reported earlier for Shigella species (6, 21). For cefotaxime, this could be due, at least in part, to the presence of the beta -lactamase reported here, since a decrease in the MIC was observed in the presence of clavulanic acid for strain PB-10. The higher ceftazidime MIC could not be correlated with beta -lactamase activity, particularly since there was no decrease in the MIC in the presence of clavulanate.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   In vitro susceptibilities of S. dysenteriae and transconjugant to beta -lactam antibiotics

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the cell lysate and the partially purified beta -lactamase of strain PB-10, followed by renaturation and overlay of gels with nitrocefin (12), showed the presence of a single band of beta -lactamase activity, with an approximate Mr of 29,000 ± 2,000 (mean ± standard deviation). Isoelectric focusing of the reference SHV-1 enzyme as well (3) as crude and partially purified beta -lactamase of PB-10, followed by overlay with nitrocefin, showed in each case a single band with beta -lactamase activity at an isoelectric point of 7.6 ± 0.2, which corresponded to that reported for SHV enzymes (2, 5).

The hydrolysis of cephaloridine and of almost all other cephalosporins tested was much slower than that of benzylpenicillin, nitrocefin being the only exception (Table 2). The oxyiminocephalosporins cefotaxime, cefuroxime, and ceftizoxime were hydrolyzed at measurable rates. No detectable hydrolytic activity was observed for ceftazidime, cefoxitin, cefsulodin, aztreonam, or imipenem. Also, these antibiotics failed to inhibit the enzyme. Unlike other SHV enzymes, the PB-10 enzyme hydrolyzed oxacillin and cloxacillin at appreciable rates. Comparison of relative rates of hydrolysis of beta -lactams by a reference SHV-1 enzyme and the beta -lactamase harbored by pMK105 demonstrate that, unlike the reference SHV-1 enzyme, the beta -lactamase produced by pMK105 hydrolyzed oxacillin. Cefotaxime was hydrolyzed by this enzyme, whereas its hydrolysis could not be measured with the reference SHV-1 enzyme. Sensitivity to clavulanic acid is characteristic of TEM and SHV enzymes. The 50% inhibitory concentrations (IC50) of clavulanic acid and sulbactam were determined by incubating the enzyme with either inhibitor for 10 min prior to the addition of benzylpenicillin (1 mM). The IC50 was determined graphically. For clavulanic acid, the values were 2 and 40 nM, while for sulbactam, the values were 17,000 and 30,000 nM for the reference strain SHV-1 and the S. dysenteriae enzyme, respectively. The S. dysenteriae enzyme was therefore less susceptible to clavulanic acid and sulbactam than the SHV-1 enzyme.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 2.   Hydrolysis parameters for SHV-1 and SHV-11 beta -lactamases for selected beta -lactamsc

The nucleotide sequence (EMBL nucleotide sequence database, accession no. Y18299) of the plasmid pMK105 revealed a 286-amino-acid open reading frame. The nucleotide sequence corresponding to positions 1 through 286 of the deduced amino acid sequence was identical to that reported for the Klebsiella pneumoniae SHV-1a (or SHV-11) (GenBank accession no. X98101), except for a silent CAC-to-CAT mutation encoding histidine 108. Mutations of the plasmid-determined TEM, SHV, and OXA beta -lactamases that enhance their affinity for expanded-spectrum cephalosporins usually occur between positions 104 and 240. These mutations have resulted in roomier active-site cavities that permit expanded-spectrum beta -lactams with bulky side chains to enter and bind to the active site serine-70 (10, 13). With site-directed mutants it has been reported that the leuright-arrowgln substitution at position 35 on the protruding NH2 terminus (16) increases resistance to ceftazidime but reduces the MICs of all other cephalosporins tested compared to SHV-2. In our case, the situation was not comparable, since the SHV-11 enzyme has glycine at position 238 rather than serine, as in SHV-2. (8) A survey of SHV beta -lactamases in Switzerland previously led to the identification of the variant enzyme SHV-11 (15) harboring the Leuright-arrowGln substitution at position 35. In this report, K. pneumoniae KPZU-12, harboring the SHV-11 beta -lactamase, showed beta -lactam susceptibilities virtually identical to K. pneumoniae KPAA-I harboring the SHV-1 beta -lactamase. We demonstrate that the SHV-11 enzyme from S. dysenteriae hydrolyzes oxyiminocephalosporins. The hydrolysis of oxacillin and cloxacillin was intriguing.

There was little similarity of the nucleotide sequence upstream of the -10 with that of the prototype SHV-1 bla gene (14). Changes in the -35 and -10 regions are a powerful influence on promoter strength (11). In E. coli, the closer the sequence is to the consensus, the stronger the promoter (-35 consensus sequence, TTGACA; -10 consensus sequence, TATAAT) (9). The promoter comprising 5'TTGCAA'3' (-35 box) and 5'TATTCT3' (-10 box) identified in the pMK105 bla gene has been reported to increase beta -lactam resistance when coupled to the SHV-2 gene. (19). The association of the bla gene with a strong promoter likely influenced susceptibilities to beta -lactams in the present study as well.

The continued emergence of beta -lactam-resistant S. dysenteriae is of particular concern to developing countries. Surprisingly, reports of noteworthy efforts to characterize the beta -lactamases most likely to be associated with this resistance phenomenon are sparse in the literature, particularly in terms of nucleotide sequence information. Our report describes perhaps the first serious attempt both to characterize the structural bla gene of a beta -lactamase from a clinical isolate of S. dysenteriae and to biochemically characterize the elaborated enzyme. Although the leu-35right-arrowgln substitution had been reported while this work was in progress (15), its effect on substrate profile had not been investigated. Rather, conclusions had been drawn merely from an evaluation of MIC data, which may be influenced by an interplay of factors, including the permeability of the outer membrane of the hosts, the amount of beta -lactamase produced, the affinities of the target penicillin-binding proteins for the tested beta -lactam, and the involvement of efflux pumps. We demonstrate, using the SHV-1 J35R1010 as a reference enzyme, that the SHV-11 enzyme hydrolyzes oxacillin, cloxacillin, and oxyiminocephalosporins such as cefotaxime and is less sensitive to clavulanic acid. The results from our biochemical characterization of this enzyme suggest that an amino acid substitution in the protruding amino terminus of the beta -lactamase likely alters the overall conformation of the molecule and, consequently, its substrate profile. The structural basis for this needs to be investigated further.


    ACKNOWLEDGMENTS

This work was supported in part by grants from the Department of Science and Technology and the Council of Scientific and Industrial Research, government of India.


    FOOTNOTES

* Corresponding author. Mailing address: Department of Chemistry, Bose Institute, 93/1 Acharya Prafulla Chandra Rd., Calcutta 700 009, India. Phone: 91 33 350 6619. Fax: 91 33 3506790. E-mail: mani{at}boseinst.ernet.in.


    REFERENCES
Top
Abstract
Text
References

1. Altschul, S. F., T. L. Madden, A. A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402[Abstract/Free Full Text].
2. Ambler, R. P., F. W. Coulson, J.-M. Frere, J.-M. Ghuysen, B. Joris, M. Forsman, R. C. Levesque, G. Tiraby, and S. G. Waley. 1991. A standard numbering scheme for the class A beta -lactamases. Biochem. J. 276:269-270.
3. Barthelemy, M., J. Peduzzi, and R. Labia. 1988. Complete amino acid sequence of p453-plasmid-mediated PIT-2 beta -lactamase (SHV-1) Biochem. J. 251:73-79[Medline].
4. Bennish, M. L., and M. A. Salam. 1992. Rethinking options of the treatment of shigellosis. J. Antimicrob. Chemother. 30:243-247[Free Full Text].
5. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for beta -lactamase and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233[Medline].
6. Cavallo, J. D., J. Bericon, J. M. Bandet, T. Samson, M. France, and M. Meyran. 1993. Antibiotic sensitivity of 140 strains of Shigella isolated in Djibouti. Bull. Soc. Pathol. Exot. 86:35-40[Medline].
7. De Meester, F., B. Joris, G. Reckinger, C. Bellefroid-Bourguignon, J. M. Frere, and S. G. Waley. 1987. Automated analysis of enzyme inactivation phenomena. Biochem. Pharmacol. 36:2393-2403[Medline].
8. Garbarg-Chenon, A., V. Godard, R. Labia, and J.-C. Nicolas. 1990. Nucleotide sequence of SHV-2 beta -lactamase gene. Antimicrob. Agents Chemother. 34:1444-1446[Abstract/Free Full Text].
9. Hawley, D., and W. R. McClure. 1983. Compilation and analysis of Escherichia coli promoter DNA sequences. Nucleic Acids Res. 11:2237-2255[Abstract/Free Full Text].
10. Herzberg, O., and J. Moult. 1987. Bacterial resistance to beta -lactam antibiotics: crystal structure of beta -lactamase from Staphylococcus aureus PC1 at 2.5 A resolution. Science 236:694-701[Abstract/Free Full Text].
11. Kobayashi, M., K. Nagata, and A. Ishihama. 1990. Promoter selectivity of Escherichia coli RNA polymerase: effect of base substitutions in the promoter-35 region on promoter strength. Nucleic Acids Res. 18:7367-7372[Abstract/Free Full Text].
12. Matthew, M., A. M. Harris, M. J. Marshall, and G. W. Ross. 1975. The use of analytical isoelectric focusing for detection and identification of beta -lactamase. J. Gen. Microbiol. 88:169-178[Medline].
13. Medeiros, A. A. 1997. Evolution and dissemination of beta -lactamases accelerated by generations of beta -lactam antibiotics. Clin. Infect. Dis. 24:S19-S45.
14. Mercier, J., and R. C. Levesque. 1990. Cloning of SHV-2, OHIO-1, and OXA-6 beta -lactamases and cloning and sequencing of SHV-1 beta -lactamase. Antimicrob. Agents Chemother. 34:1577-1583[Abstract/Free Full Text].
15. Nüesch-Inderbinen, M. T., F. H. Kayser, and H. Hächler. 1997. Survey and molecular genetics of SHV beta -lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12. Antimicrob. Agents Chemother. 41:943-949[Abstract].
16. Nüesch-Inderbinen, M. T., H. Hächler, and F. H. Kayser. 1995. New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV beta -lactamases. Antimicrob. Agents Chemother. 39:1726-1730[Abstract].
17. O'Callaghan, C. H., A. Morris, S. M. Kirby, and A. H. Shingler. 1982. Novel method for the detection of beta -lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288.
18. Phillipon, A. M., G. C. Paul, and G. A. Jacoby. 1983. Properties of PSE-2 beta -lactamase and genetic basis for its production in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 24:362-369[Abstract/Free Full Text].
19. Podbielski, A., J. Schonling, B. Melzer, K. Warnatz, and H.-G. Leusch. 1991. Molecular characterization of a new plasmid-encoded SHV-type beta -lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae. J. Gen. Microbiol. 137:569-578[Abstract/Free Full Text].
20. Pridmore, R. D. 1987. New and versatile cloning vectors with kanamycin-resistance marker. Gene 56:309-312[Medline].
21. Verbist, L., and J. Verhaegen. 1980. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob. Agents Chemother. 17:807-812[Abstract/Free Full Text].


Antimicrobial Agents and Chemotherapy, August 1999, p. 2081-2083, Vol. 43, No. 8
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Sivapalasingam, S., Nelson, J. M., Joyce, K., Hoekstra, M., Angulo, F. J., Mintz, E. D. (2006). High Prevalence of Antimicrobial Resistance among Shigella Isolates in the United States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002. Antimicrob. Agents Chemother. 50: 49-54 [Abstract] [Full Text]  
  • Paterson, D. L., Bonomo, R. A. (2005). Extended-Spectrum {beta}-Lactamases: a Clinical Update. Clin. Microbiol. Rev. 18: 657-686 [Abstract] [Full Text]  
  • Huang, I-F., Chiu, C.-H., Wang, M.-H., Wu, C.-Y., Hsieh, K.-S., Chiou, C. C. (2005). Outbreak of Dysentery Associated with Ceftriaxone-Resistant Shigella sonnei: First Report of Plasmid-Mediated CMY-2-Type AmpC {beta}-Lactamase Resistance in S. sonnei. J. Clin. Microbiol. 43: 2608-2612 [Abstract] [Full Text]  
  • Dubois, V., Poirel, L., Arpin, C., Coulange, L., Bebear, C., Nordmann, P., Quentin, C. (2004). SHV-49, a Novel Inhibitor-Resistant {beta}-Lactamase in a Clinical Isolate of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48: 4466-4469 [Abstract] [Full Text]  
  • Kim, S., Kim, J., Kang, Y., Park, Y., Lee, B. (2004). Occurrence of Extended-Spectrum {beta}-Lactamases in Members of the Genus Shigella in the Republic of Korea. J. Clin. Microbiol. 42: 5264-5269 [Abstract] [Full Text]  
  • Rahman, M., Shoma, S., Rashid, H., Siddique, A. K., Nair, G. B., Sack, D. A. (2004). Extended-spectrum {beta}-lactamase-mediated third-generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrob Chemother 54: 846-847 [Full Text]  
  • Ford, P. J., Avison, M. B. (2004). Evolutionary mapping of the SHV {beta}-lactamase and evidence for two separate IS26-dependent blaSHV mobilization events from the Klebsiella pneumoniae chromosome. J Antimicrob Chemother 54: 69-75 [Abstract] [Full Text]  
  • Kim, J., Shin, H.-S., Seol, S.-Y., Cho, D.-T. (2002). Relationship between blaSHV-12 and blaSHV-2a in Korea. J Antimicrob Chemother 49: 261-267 [Abstract] [Full Text]  
  • Pai, H., Choi, E.-H., Lee, H.-J., Hong, J. Y., Jacoby, G. A. (2001). Identification of CTX-M-14 Extended-Spectrum {beta}-Lactamase in Clinical Isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J. Clin. Microbiol. 39: 3747-3749 [Abstract] [Full Text]  
  • Madinier, I., Fosse, T., Giudicelli, J., Labia, R. (2001). Cloning and Biochemical Characterization of a Class A {beta}-Lactamase from Prevotella intermedia. Antimicrob. Agents Chemother. 45: 2386-2389 [Abstract] [Full Text]  
  • Fortineau, N., Naas, T., Gaillot, O., Nordmann, P. (2001). SHV-type extended-spectrum {beta}-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother 47: 685-688 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ahamed, J.
Right arrow Articles by Kundu, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahamed, J.
Right arrow Articles by Kundu, M.